During 2021, we have continued our internationalization in terms of grants, publications, participation in different consortia, and most importantly our involvement in the design of clinical guidelines for liver diseases in Europe and involvement in European Institutions for Liver Diseases. To be highlighted is the contribution our members to Baveno VII recommendations on Portal Hypertension, being part of the Governing Board of EASL, participating in the Scientific Committee of AEEH, and the coordination and involvement in several H2020 projects.
Group Leader
Joan Genescà Ferrer
Principal Investigator (PI)
Maria Buti Ferret, Isabel Campos Varela, Juan Ignacio Esteban Mur, Maria Martell Pérez-Alcalde, Beatriz Minguez Rosique, Juan Manuel Pericàs Pulido, Josep Quer Sivila, Maria Del Mar Riveiro Barciela, Macarena Simon-Talero Horga, Victor Manuel Vargas Blasco, Meritxell Ventura Cots
Researchers
Caroline Melani Adombi, Marta Bes Maijo, Lluis Castells Fusté, Maria Isabel Costafreda Salvany, Rafael Esteban Mur, Diana Hide Alferez, Immaculada Raurell Saborit, Maria Luisa Roade Tato, David Tabernero Caellas, Lluís Viladomiu Catà
PhD Students
Aurora Barbera Belles, Ana Barreira Diaz, María Bermúdez Ramos, Mar Gil Soler, Cesar Jimenez Hernandez, Jordi Llaneras Artigues, Meritxell Llorens Revull, Joan Martínez Campreciós, Adriana Palom Agusti, Mònica Pons Delgado, Jesus Manuel Rivera Esteban, Elena Vargas Accarino, Judit Vidal Gonzalez
Lab Technicians
Els que hi ha actualment a la web
Nursing and Technical Staff
Susana Anton Calvo, Emma Bigas Alsina, Laura Cecconi, Sergi Colomer Castell, Elena de Sena Fernández, Anna Feliu Prius, Damir Garcia Cehic, Montserrat Gomez Perez, Monica Higuera Urbano, Ramiro Manzano Nuñez, Daniel Martinez Vazquez, Ester Palacio Gutierrez, Mª Nieves Palomo Merchan, Marcella Salzano, Maria Margarita Torrens Buscató, Gloria Torres Pérez, Judit Vico Romero
89
PUBLICATIONS
825
IMPACT FACTOR
9.27
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
J Hepatol. 2021 Apr;74(4):944-951.
DOI: 10.1016/j.jhep.2021.01.032
IF: 25.08
Caraceni P, Vargas V, Sola E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Gines P
The use of Rifaximin in Patients with Cirrhosis.
Hepatology. 2021 Sep;74(3):1660-1673.
DOI: 10.1002/hep.31708
IF: 17.43
Llaneras J, Riveiro-Barciela M, Rando-Segura A, Marcos-Fosch C, Roade L, Velazquez F, Rodriguez-Frias F, Esteban R, Buti M
Etiologies and Features of Acute Viral Hepatitis in Spain.
Clin Gastroenterol Hepatol. 2021 May;19(5):1030-1037.
DOI: 10.1016/j.cgh.2020.07.006
IF: 11.38
Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, Stefanescu H, Ma MM, Mandorfer M, Mergeay-Fabre M, Procopet B, Schwabl P, Ferlitsch A, Semmler G, Berzigotti A, Tsochatzis E, Bureau C, Reiberger T, Bosch J, Abraldes JG, Genesca J
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Am J Gastroenterol. 2021 Apr;116(4):723-732.
DOI: 10.14309/ajg.0000000000000994
IF: 10.86
Campos-Varela I, Dodge JL, Terrault NA, Brandman D, Price JC
Non-viral Liver Disease is the Leading Indication for Liver Transplant in the U.S. in Persons Living with Human Immunodeficiency Virus.
Am J Transplant. 2021 Sep;21(9):3148-3156.
DOI: 10.1111/ajt.16569
IF: 8.09
Biodegradable nanoparticles of Simvastatin as new therapeutic tool for chronic liver disease (NANOSIM)
Principal Investigator: Joan Genescà Ferrer (collaborators: Maria Martell Pérez-Alcalde, Salvador Augustin Recio)
Agency: Instituto de Salud Carlos III
Funding: 199,946.45 €
Period: 2019-2021
Liverhope: Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis
Principal Investigator: Victor Manuel Vargas Blasco
Agency: European Commission
Funding: 342,055 €
Period: 2017-2021
Screening for liver fibrosis – population-based study across European countries
Principal Investigator: Juan Manuel Pericàs Pulido
Agency: European Commission
Funding: 172,385.95 €
Period: 2020-2024
Immune profiling to guide host-directed interventions to cure HBV infections
Principal Investigator: Maria Buti Ferret
Agency: European Commission
Funding: 250,000 €
Period: 2020-2024
EU Patient- cEntric clinicAl tRial pLatform – EU PEARL.
Principal Investigator: Joan Genescà Ferrer (collaborators: Juan Manuel Pericàs Pulido, Salvador Augustin Recio, Jesus Manuel Rivera Esteban)
Agency: The Innovative Medicines Initiative
Funding: 1,987,375 €
Period: 2019-2023
